Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?

Detalles Bibliográficos
Autor principal: Riva, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa UK, Ltd. 2013
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833714/
https://www.ncbi.nlm.nih.gov/pubmed/23931143
http://dx.doi.org/10.1517/14740338.2013.829452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833714/
https://www.ncbi.nlm.nih.gov/pubmed/23931143
http://dx.doi.org/10.1517/14740338.2013.829452

Ejemplares similares